ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year

Immunoprecise and Genmab enter into a technology partnership targeting infectious disease Immunoprecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical evaluation Commenced trading on Nasdaq stock exchange Announced positive data from pre-clinical study of TATX-03 Polytope™ monoclonal antibody cocktail candidate against COVID-19 VICTORIA, BRITISH COLUMBIA March 17, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the […]